https://trial.medpath.com/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/press-release-six-month-data-from-alfapump-r-pivotal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/press-release-six-month-data-from-alfapump-r-pivotal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-appoints-pharmaceutical-leader 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-appoints-pharmaceutical-leader 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-receives-ema-orphan-medicinal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-receives-ema-orphan-medicinal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wt-7-shows-acceptable-safety-profile-in-relapsed 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wt-7-shows-acceptable-safety-profile-in-relapsed 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/atopic-dermatitis-clinical-trials-2024-a-comprehensive-overview 2025-01-06T15:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atopic-dermatitis-clinical-trials-2024-a-comprehensive-overview 2025-01-06T15:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/imetelstat-plus-ruxolitinib-demonstrates-tolerable-safety-profile-in-myelofibrosis-onclive 2025-01-06T15:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imetelstat-plus-ruxolitinib-demonstrates-tolerable-safety-profile-in-myelofibrosis-onclive 2025-01-06T15:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-price-target-increased-by-brookline 2025-01-06T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-price-target-increased-by-brookline 2025-01-06T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-seeks-to-join-lawsuit-on-compounded-drugs-stat-news 2025-01-06T14:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-seeks-to-join-lawsuit-on-compounded-drugs-stat-news 2025-01-06T14:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/esophageal-cancer-market-report-2034-epidemiology-pipeline-therapies-and-latest-approvals 2025-01-06T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esophageal-cancer-market-report-2034-epidemiology-pipeline-therapies-and-latest-approvals 2025-01-06T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-pharmaceuticals-appoints-dan-monahan-as-chief-commercial-officer-morningstar 2025-01-06T14:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-pharmaceuticals-appoints-dan-monahan-as-chief-commercial-officer-morningstar 2025-01-06T14:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-stock-titan 2025-01-06T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-stock-titan 2025-01-06T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/anito-cel-demonstrates-safety-and-early-efficacy-in-r-r-multiple-myeloma-onclive 2025-01-06T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anito-cel-demonstrates-safety-and-early-efficacy-in-r-r-multiple-myeloma-onclive 2025-01-06T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/investigators-hope-for-potential-breakthrough-in-dual-cellular-therapy-approach-for 2025-01-06T13:58:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investigators-hope-for-potential-breakthrough-in-dual-cellular-therapy-approach-for 2025-01-06T13:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-s-netherton-syndrome-treatment-shows-dramatic-83-symptom-reduction-in-clinical-trial 2025-01-06T13:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-s-netherton-syndrome-treatment-shows-dramatic-83-symptom-reduction-in-clinical-trial 2025-01-06T13:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/nocira-r-grows-patent-portfolio-for-personalized-adaptive-migraine-treatments 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nocira-r-grows-patent-portfolio-for-personalized-adaptive-migraine-treatments 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/unity-biotech-appoints-syfovre-developer-dr-grossi-as-cmo-ahead-of-key-dme-trial 2025-01-06T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unity-biotech-appoints-syfovre-developer-dr-grossi-as-cmo-ahead-of-key-dme-trial 2025-01-06T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-provides-december-tigris-trial-update-financial-post 2025-01-06T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-provides-december-tigris-trial-update-financial-post 2025-01-06T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-launches-pivotal-phase-1-2-trial-for-novel-itp-treatment-cid-103 2025-01-06T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-launches-pivotal-phase-1-2-trial-for-novel-itp-treatment-cid-103 2025-01-06T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviews-cutx-101-for-menkes-disease-treatment-investing-com 2025-01-06T13:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviews-cutx-101-for-menkes-disease-treatment-investing-com 2025-01-06T13:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/stroke-care-device-maker-wellumio-expands-u-s-footprint-massdevice 2025-01-06T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stroke-care-device-maker-wellumio-expands-u-s-footprint-massdevice 2025-01-06T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/iparomlimab-tuvonralimab-plus-chemo-bevacizumab-yields-responses-in-recurrent-onclive 2025-01-06T13:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iparomlimab-tuvonralimab-plus-chemo-bevacizumab-yields-responses-in-recurrent-onclive 2025-01-06T13:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/extended-paxlovid-may-help-some-people-with-long-covid-uc-san-francisco 2025-01-06T13:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-paxlovid-may-help-some-people-with-long-covid-uc-san-francisco 2025-01-06T13:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-updates-shareholders-on-progress-and-2025-outlook 2025-01-06T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lineage-cell-therapeutics-updates-shareholders-on-progress-and-2025-outlook 2025-01-06T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic 2025-01-06T12:46:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic 2025-01-06T12:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/vyne-therapeutics-completes-phase-2b-trial-enrollment-for-novel-vitiligo-treatment-vyn201 2025-01-06T12:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyne-therapeutics-completes-phase-2b-trial-enrollment-for-novel-vitiligo-treatment-vyn201 2025-01-06T12:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/xortx-launches-xrx-026-program-for-allopurinol-intolerant-gout-patients-targets-fda-approval 2025-01-06T12:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xortx-launches-xrx-026-program-for-allopurinol-intolerant-gout-patients-targets-fda-approval 2025-01-06T12:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-signs-business-research-globenewswire 2025-01-06T12:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-signs-business-research-globenewswire 2025-01-06T12:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/essex-bio-technology-completes-phase-3-study-for-wet-amd-treatment-markets-insider 2025-01-06T11:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essex-bio-technology-completes-phase-3-study-for-wet-amd-treatment-markets-insider 2025-01-06T11:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/uk-conditionally-approves-amgen-s-drug-for-aggressive-lung-cancer-in-pretreated-patients 2025-01-06T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-conditionally-approves-amgen-s-drug-for-aggressive-lung-cancer-in-pretreated-patients 2025-01-06T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nasdaq-grants-revelation-biosciences-inc-continued-listing-stock-titan 2025-01-06T11:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasdaq-grants-revelation-biosciences-inc-continued-listing-stock-titan 2025-01-06T11:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/glecirasib-in-kras-g12c-mutated-nonsmall-cell-lung-cancer-a-phase-2b-trial-nature 2025-01-06T11:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glecirasib-in-kras-g12c-mutated-nonsmall-cell-lung-cancer-a-phase-2b-trial-nature 2025-01-06T11:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/selumetinib-in-adults-with-nf1-and-inoperable-plexiform-neurofibroma-a-phase-2-trial 2025-01-06T11:13:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selumetinib-in-adults-with-nf1-and-inoperable-plexiform-neurofibroma-a-phase-2-trial 2025-01-06T11:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-for-cancer-using-routine-blood 2025-01-06T11:13:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-for-cancer-using-routine-blood 2025-01-06T11:13:42+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-acquires-dura-medical-to-expand-interventional-psychiatry-network-in-florida 2025-01-06T11:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-therapeutics-acquires-dura-medical-to-expand-interventional-psychiatry-network-in-florida 2025-01-06T11:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-copd 2025-01-06T11:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-copd 2025-01-06T11:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-06T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-06T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/open-label-randomised-clinical-trial-investigating-whether-robot-assisted-kidney 2025-01-06T10:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/open-label-randomised-clinical-trial-investigating-whether-robot-assisted-kidney 2025-01-06T10:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-secures-key-patent-allowances-for-accum-r-multimer-technology-and-vaccine-platform 2025-01-06T10:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-secures-key-patent-allowances-for-accum-r-multimer-technology-and-vaccine-platform 2025-01-06T10:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-optimal-age-to-stop-colorectal-cancer-screening-based-on-individual-risk-factors 2025-01-06T09:51:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-optimal-age-to-stop-colorectal-cancer-screening-based-on-individual-risk-factors 2025-01-06T09:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/the-biotech-scorecard-for-the-first-quarter-16-stock-moving-events-to-watch 2025-01-06T09:36:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-biotech-scorecard-for-the-first-quarter-16-stock-moving-events-to-watch 2025-01-06T09:36:23+00:00 hourly 0.9 https://trial.medpath.com/news/do-glp-1-receptor-agonists-increase-the-risk-of-suicide-in-patients-news-medical 2025-01-06T09:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/do-glp-1-receptor-agonists-increase-the-risk-of-suicide-in-patients-news-medical 2025-01-06T09:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/2025-cure-parkinson-s-research-highlights-from-the-last-year-and-insights-for-the-year-ahead 2025-01-06T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2025-cure-parkinson-s-research-highlights-from-the-last-year-and-insights-for-the-year-ahead 2025-01-06T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/sidra-medicine-advances-innovation-and-expands-precision-medicine-efforts 2025-01-06T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sidra-medicine-advances-innovation-and-expands-precision-medicine-efforts 2025-01-06T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-stock-titan 2025-01-06T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-stock-titan 2025-01-06T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-transformed-indolent-non-hodgkin-lymphoma 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-for-transformed-indolent-non-hodgkin-lymphoma 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-shows-superior-fracture-prevention-in-dialysis-patients-despite-cardiovascular-risks 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-shows-superior-fracture-prevention-in-dialysis-patients-despite-cardiovascular-risks 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-secures-additional-11-5-million-in-financing-to-advance-gene-circuit-based-therapies 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-secures-additional-11-5-million-in-financing-to-advance-gene-circuit-based-therapies 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/naya-biosciences-expands-oncology-pipeline-with-new-antibody 2025-01-06T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naya-biosciences-expands-oncology-pipeline-with-new-antibody 2025-01-06T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/sagimet-biosciences-to-present-fasn-inhibitor-research-at-mash-tag-2025-conference 2025-01-06T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagimet-biosciences-to-present-fasn-inhibitor-research-at-mash-tag-2025-conference 2025-01-06T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/qpop-platform-shows-87-success-rate-in-personalizing-aml-treatment-selection 2025-01-06T08:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qpop-platform-shows-87-success-rate-in-personalizing-aml-treatment-selection 2025-01-06T08:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/nuclein-achieves-dual-fda-510-k-clearance-and-clia-waiver-for-dash-r-sars-cov-2-flu-a-b-test 2025-01-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclein-achieves-dual-fda-510-k-clearance-and-clia-waiver-for-dash-r-sars-cov-2-flu-a-b-test 2025-01-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-completes-enrollment-for-lotis-5-phase-3-trial-reinforcing-zynlonta-s-potential-in-dlbcl-treatment 2025-01-06T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-therapeutics-completes-enrollment-for-lotis-5-phase-3-trial-reinforcing-zynlonta-s-potential-in-dlbcl-treatment 2025-01-06T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/orbis-medicines-raises-eur90m-series-a-to-advance-oral-macrocycle-drug-development 2025-01-06T07:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbis-medicines-raises-eur90m-series-a-to-advance-oral-macrocycle-drug-development 2025-01-06T07:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-ec-extends-the-approval-of-evkeeza-r-globenewswire 2025-01-06T07:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-ec-extends-the-approval-of-evkeeza-r-globenewswire 2025-01-06T07:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/large-meta-analysis-reveals-link-between-high-fluoride-exposure-and-reduced-iq-in-children 2025-01-06T06:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-meta-analysis-reveals-link-between-high-fluoride-exposure-and-reduced-iq-in-children 2025-01-06T06:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-insulin-shows-promise-in-combating-diabetes-related-cognitive-decline 2025-01-06T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-insulin-shows-promise-in-combating-diabetes-related-cognitive-decline 2025-01-06T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/nmd-pharma-announces-fda-orphan-drug-designation-granted-to-globenewswire 2025-01-06T06:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmd-pharma-announces-fda-orphan-drug-designation-granted-to-globenewswire 2025-01-06T06:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/natural-weight-loss-drug-as-effective-as-ozempic-and-without-side-effects-academics-claim 2025-01-06T05:58:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natural-weight-loss-drug-as-effective-as-ozempic-and-without-side-effects-academics-claim 2025-01-06T05:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/opinion-the-cocktail-recipe-that-will-cure-alzheimer-s-biospace 2025-01-06T05:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opinion-the-cocktail-recipe-that-will-cure-alzheimer-s-biospace 2025-01-06T05:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease-biospace 2025-01-06T05:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease-biospace 2025-01-06T05:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/a-randomized-double-blind-placebo-controlled-trial-protocol-for-a-fu-jpr-dove-medical-press 2025-01-06T05:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-randomized-double-blind-placebo-controlled-trial-protocol-for-a-fu-jpr-dove-medical-press 2025-01-06T05:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/brainstorm-advances-with-phase-3b-trial-of-nurown-r-in-als-and-secures-new-patent-for-exosome-technology 2025-01-06T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainstorm-advances-with-phase-3b-trial-of-nurown-r-in-als-and-secures-new-patent-for-exosome-technology 2025-01-06T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/adjunctive-pcsk9-inhibitor-evolocumab-in-the-prevention-of-early-neurological 2025-01-06T04:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjunctive-pcsk9-inhibitor-evolocumab-in-the-prevention-of-early-neurological 2025-01-06T04:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-nurse-visits-show-promise-in-clinical-trials-industry-survey-reveals-91-retention-benefit 2025-01-06T03:44:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-nurse-visits-show-promise-in-clinical-trials-industry-survey-reveals-91-retention-benefit 2025-01-06T03:44:23+00:00 hourly 0.9 https://trial.medpath.com/news/observational-pilot-study-of-switching-from-entecavir-to-tenofovir-alafenamide-in-patients-with 2025-01-06T03:30:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/observational-pilot-study-of-switching-from-entecavir-to-tenofovir-alafenamide-in-patients-with 2025-01-06T03:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/australia-launches-a-35-7m-grant-initiative-to-enhance-clinical-trial-infrastructure 2025-01-06T02:29:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-launches-a-35-7m-grant-initiative-to-enhance-clinical-trial-infrastructure 2025-01-06T02:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/effect-of-intravenous-urokinase-vs-best-medicine-treatment-on-functional-outcome-for 2025-01-06T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/effect-of-intravenous-urokinase-vs-best-medicine-treatment-on-functional-outcome-for 2025-01-06T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/health-check-percheron-board-addresses-shareholders-after-failed-phase-2b-trial 2025-01-06T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-check-percheron-board-addresses-shareholders-after-failed-phase-2b-trial 2025-01-06T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/new-nmosd-treatment-gains-pbs-recommendation-ms-australia 2025-01-06T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-nmosd-treatment-gains-pbs-recommendation-ms-australia 2025-01-06T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-r-d-resource-allocation-the-hidden-risks-of-over-investing-in-single-drug-development 2025-01-06T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-r-d-resource-allocation-the-hidden-risks-of-over-investing-in-single-drug-development 2025-01-06T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/guess-which-all-ords-asx-healthcare-stock-just-surged-11-on-fda-news-motley-fool 2025-01-06T00:42:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guess-which-all-ords-asx-healthcare-stock-just-surged-11-on-fda-news-motley-fool 2025-01-06T00:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-national-medical-products-administration-nmpa-approves-vyloy-markets-data 2025-01-06T00:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-national-medical-products-administration-nmpa-approves-vyloy-markets-data 2025-01-06T00:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/tcl1a-protein-identified-as-predictor-of-blinatumomab-response-in-relapsed-b-all 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcl1a-protein-identified-as-predictor-of-blinatumomab-response-in-relapsed-b-all 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/non-opioid-pain-relievers-outperform-opioids-after-dental-surgery 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-opioid-pain-relievers-outperform-opioids-after-dental-surgery 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-trial-for-geographic-atrophy-shows-limited-efficacy-despite-sustained-factor-i-expression 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-trial-for-geographic-atrophy-shows-limited-efficacy-despite-sustained-factor-i-expression 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-insights-on-hypertension-treatment-combination-pills-and-medication-timing 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-insights-on-hypertension-treatment-combination-pills-and-medication-timing 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-announces-positive-reblozyl-phase-3-results-for-mds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-announces-positive-reblozyl-phase-3-results-for-mds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-a-singapore-biotech-revolutionizes-cancer-treatment-using-donor-immune-cells 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-a-singapore-biotech-revolutionizes-cancer-treatment-using-donor-immune-cells 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-to-host-webcast-to-discuss-successful 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-to-host-webcast-to-discuss-successful 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insulin-beats-oral-alternatives-for-gestational-diabetes-outcome 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulin-beats-oral-alternatives-for-gestational-diabetes-outcome 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brentuximab-vedotin-shows-strong-real-world-efficacy-in-chinese-alcl-patients-multi-center-study-finds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brentuximab-vedotin-shows-strong-real-world-efficacy-in-chinese-alcl-patients-multi-center-study-finds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/technoderma-medicines-reports-positive-phase-2a-trial-results-for-tdm-180935-in-atopic-dermatitis 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/technoderma-medicines-reports-positive-phase-2a-trial-results-for-tdm-180935-in-atopic-dermatitis 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucarpidase-for-treatment-of-high-dose-methotrexate 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucarpidase-for-treatment-of-high-dose-methotrexate 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-clinical-results-and-market-potential-drive-buy-rating-for-oculis-holding 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-clinical-results-and-market-potential-drive-buy-rating-for-oculis-holding 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-trodelvy-fails-in-bladder-cancer-trial 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-trodelvy-fails-in-bladder-cancer-trial 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-receives-fda-approval-for-rsv-vaccine-mresvia 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-receives-fda-approval-for-rsv-vaccine-mresvia 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tanvex-biopharma-faces-second-fda-crl-for-herceptin-biosimilar 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tanvex-biopharma-faces-second-fda-crl-for-herceptin-biosimilar 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-test-to-identify-patients-at-risk-of-opioid-use-disorder 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-test-to-identify-patients-at-risk-of-opioid-use-disorder 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-technologies-advances-bladder-cancer-treatment-with-promising-phase-ii-trial-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-technologies-advances-bladder-cancer-treatment-with-promising-phase-ii-trial-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-much-anticipated-guidance-on-pulse-oximeters 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-much-anticipated-guidance-on-pulse-oximeters 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-price-target-raised-to-31-from-23-at-bofa 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-price-target-raised-to-31-from-23-at-bofa 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mepolizumab-in-chronic-rhinosinusitis-with-nasal-polyps-real-life-data 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mepolizumab-in-chronic-rhinosinusitis-with-nasal-polyps-real-life-data 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-panel-approves-sage-s-novel-antidepressant-for-postnatal-depression-rejects-alkermes-treatment 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-panel-approves-sage-s-novel-antidepressant-for-postnatal-depression-rejects-alkermes-treatment 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/citius-shares-jump-after-reporting-positive-results-from-early-study-of 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citius-shares-jump-after-reporting-positive-results-from-early-study-of 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-transplants-show-promise-in-alleviating-gi-symptoms-in-type-1-diabetes-patients 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-transplants-show-promise-in-alleviating-gi-symptoms-in-type-1-diabetes-patients 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-asundexian-to-phase-3-trials-despite-mixed-phase-2-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-asundexian-to-phase-3-trials-despite-mixed-phase-2-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sage-and-biogen-s-zuranolone-shows-promise-in-phase-3-trials-but-faces-commercial-uncertainty 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sage-and-biogen-s-zuranolone-shows-promise-in-phase-3-trials-but-faces-commercial-uncertainty 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-retina-and-vitreous-treatments-highlighted-in-recent-studies-and-collaborations 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-retina-and-vitreous-treatments-highlighted-in-recent-studies-and-collaborations 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-launches-gene-therapeutics-center 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-launches-gene-therapeutics-center 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-regroups-after-clinical-trial-results-vows-to-continue-to-conserve 2025-01-05T23:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-regroups-after-clinical-trial-results-vows-to-continue-to-conserve 2025-01-05T23:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/ebr-systems-awaits-fda-inspection-for-wireless-cardiac-device-tipranks-com 2025-01-05T23:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebr-systems-awaits-fda-inspection-for-wireless-cardiac-device-tipranks-com 2025-01-05T23:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/rct-2100-by-recode-therapeutics-for-cystic-fibrosis-likelihood-of-approval 2025-01-05T21:55:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rct-2100-by-recode-therapeutics-for-cystic-fibrosis-likelihood-of-approval 2025-01-05T21:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/los-angles-shigellosis-outbreak-caused-by-mutation-vax-before-travel 2025-01-05T19:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/los-angles-shigellosis-outbreak-caused-by-mutation-vax-before-travel 2025-01-05T19:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/dopamine-s-surprising-breakthrough-in-alzheimer-s-treatment-rolling-out 2025-01-05T19:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dopamine-s-surprising-breakthrough-in-alzheimer-s-treatment-rolling-out 2025-01-05T19:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-approves-novartis-protocol-amendment-proposal-for-tin816-study-in-sepsis 2025-01-05T19:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-approves-novartis-protocol-amendment-proposal-for-tin816-study-in-sepsis 2025-01-05T19:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/lanarkshire-dad-with-mnd-backs-ps350k-campaign-to-help-fund-miracle-drug-trial-glasgow-live 2025-01-05T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lanarkshire-dad-with-mnd-backs-ps350k-campaign-to-help-fund-miracle-drug-trial-glasgow-live 2025-01-05T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-action-update-december-2025-approval-designations-and-clinical-hold 2025-01-05T17:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-action-update-december-2025-approval-designations-and-clinical-hold 2025-01-05T17:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-mrna-vaccine-revolutionizes-pancreatic-cancer-treatment 2025-01-05T16:42:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-mrna-vaccine-revolutionizes-pancreatic-cancer-treatment 2025-01-05T16:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/marine-fungi-a-promising-source-of-novel-antibiotics-in-the-fight-against-drug-resistance 2025-01-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marine-fungi-a-promising-source-of-novel-antibiotics-in-the-fight-against-drug-resistance 2025-01-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-warning-for-secondary-malignancies-warranted-or-not-medpage-today 2025-01-05T15:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-warning-for-secondary-malignancies-warranted-or-not-medpage-today 2025-01-05T15:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-toolkit-shows-promise-in-improving-sickle-cell-trait-documentation-during-infancy 2025-01-05T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-toolkit-shows-promise-in-improving-sickle-cell-trait-documentation-during-infancy 2025-01-05T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lung-protective-ventilation-guided-by-driving-pressure-improves-pulmonary-outcomes-in-nature 2025-01-05T11:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-protective-ventilation-guided-by-driving-pressure-improves-pulmonary-outcomes-in-nature 2025-01-05T11:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-telisotuzumab-adizutecan-shows-promise-across-multiple-solid-tumors 2025-01-05T10:00:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-telisotuzumab-adizutecan-shows-promise-across-multiple-solid-tumors 2025-01-05T10:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-advances-astx-295-novel-mdm2-inhibitor-in-glioblastoma-and-multiple-cancer-types 2025-01-05T09:37:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-advances-astx-295-novel-mdm2-inhibitor-in-glioblastoma-and-multiple-cancer-types 2025-01-05T09:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-scar-02-shows-promise-for-multiple-autoimmune-conditions 2025-01-05T09:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-scar-02-shows-promise-for-multiple-autoimmune-conditions 2025-01-05T09:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-advances-ro-7759065-development-for-metastatic-solid-tumors 2025-01-05T09:37:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-advances-ro-7759065-development-for-metastatic-solid-tumors 2025-01-05T09:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-novel-nlrx1-targeting-drug-amelenodor-for-inflammatory-bowel-disease-treatment 2025-01-05T09:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-novel-nlrx1-targeting-drug-amelenodor-for-inflammatory-bowel-disease-treatment 2025-01-05T09:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/synthekine-advances-novel-il-2-based-combination-therapy-for-refractory-cll-treatment 2025-01-05T09:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthekine-advances-novel-il-2-based-combination-therapy-for-refractory-cll-treatment 2025-01-05T09:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-advances-novel-liposomal-vaccine-jnj-2056-for-alzheimer-s-and-tauopathies 2025-01-05T09:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-advances-novel-liposomal-vaccine-jnj-2056-for-alzheimer-s-and-tauopathies 2025-01-05T09:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/could-lymph-node-surgery-be-the-answer-for-treating-alzheimer-s-disease 2025-01-05T09:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-lymph-node-surgery-be-the-answer-for-treating-alzheimer-s-disease 2025-01-05T09:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/dragonboat-biopharmaceutical-advances-cetuximab-biosimilar-development-for-multiple-cancer-indications 2025-01-05T08:56:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dragonboat-biopharmaceutical-advances-cetuximab-biosimilar-development-for-multiple-cancer-indications 2025-01-05T08:56:22+00:00 hourly 0.9 https://trial.medpath.com/news/high-fiber-diet-shows-promise-in-obesity-management-opening-new-paths-for-pharmaceutical-development 2025-01-05T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-fiber-diet-shows-promise-in-obesity-management-opening-new-paths-for-pharmaceutical-development 2025-01-05T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-achieves-breakthrough-in-bci-clinical-trials-enabling-patient-to-convert-thoughts-into 2025-01-05T05:51:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-achieves-breakthrough-in-bci-clinical-trials-enabling-patient-to-convert-thoughts-into 2025-01-05T05:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/dual-biopsy-approach-enhances-precision-medicine-success-in-lung-cancer-treatment 2025-01-05T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-biopsy-approach-enhances-precision-medicine-success-in-lung-cancer-treatment 2025-01-05T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-metabolic-signatures-show-promise-for-earlier-pancreatic-cancer-detection-and-prognosis 2025-01-05T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-metabolic-signatures-show-promise-for-earlier-pancreatic-cancer-detection-and-prognosis 2025-01-05T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-outlines-patient-specific-approach-for-io-combinations-in-unresectable-hcc-treatment 2025-01-05T03:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-outlines-patient-specific-approach-for-io-combinations-in-unresectable-hcc-treatment 2025-01-05T03:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-the-times 2025-01-05T01:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-the-times 2025-01-05T01:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/ariad-speeding-ponatinib-to-market 2025-01-05T00:53:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ariad-speeding-ponatinib-to-market 2025-01-05T00:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-her2-breast-cancer-diagnostic 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-her2-breast-cancer-diagnostic 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-lon-imm-stock-price-down-5-6 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-lon-imm-stock-price-down-5-6 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-in-clinical-trials-a-week-of-promising-developments 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-in-clinical-trials-a-week-of-promising-developments 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-lilly-s-non-opioid-pain-drug-tanezumab-shows-promise-in-phase-3-trial 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-lilly-s-non-opioid-pain-drug-tanezumab-shows-promise-in-phase-3-trial 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-partners-with-biontech-on-clinical-trials-of-mrna-cancer-therapies 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-partners-with-biontech-on-clinical-trials-of-mrna-cancer-therapies 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-dicerna-for-hepatitis-b-gene-silencing-drug 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-dicerna-for-hepatitis-b-gene-silencing-drug 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-s-thinking-healthy-programme-shows-promise-in-treating-perinatal-depression-in-chinese-hospitals 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-s-thinking-healthy-programme-shows-promise-in-treating-perinatal-depression-in-chinese-hospitals 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kadmon-prepares-fda-filing-for-gvhd-drug-belumosudil-following-phase-3-success 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kadmon-prepares-fda-filing-for-gvhd-drug-belumosudil-following-phase-3-success 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-reduces-hospitalization-and-death-risks-in-covid-19-patients-with-kidney-disease 2025-01-04T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxlovid-reduces-hospitalization-and-death-risks-in-covid-19-patients-with-kidney-disease 2025-01-04T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-986253-plus-nivolumab-ipilimumab-fails-to-boost-responses-in-advanced-melanoma 2025-01-04T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-986253-plus-nivolumab-ipilimumab-fails-to-boost-responses-in-advanced-melanoma 2025-01-04T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-the-clinical-care-of-friedreich-ataxia-through-omaveloxlone-and-skyclarys 2025-01-04T16:03:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanding-the-clinical-care-of-friedreich-ataxia-through-omaveloxlone-and-skyclarys 2025-01-04T16:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-leads-to-sustained-myasthenia-gravis-improvement 2025-01-04T13:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efgartigimod-leads-to-sustained-myasthenia-gravis-improvement 2025-01-04T13:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/etanercept-and-infliximab-biosimilars-show-no-increased-infection-risk-comparable-safety 2025-01-04T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etanercept-and-infliximab-biosimilars-show-no-increased-infection-risk-comparable-safety 2025-01-04T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/new-hope-for-fibrolamellar-carcinoma-summit-trial-findings-targeted-oncology 2025-01-04T12:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-hope-for-fibrolamellar-carcinoma-summit-trial-findings-targeted-oncology 2025-01-04T12:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/uw-madison-pioneers-ketamine-study-for-teens-with-ptsd 2025-01-04T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uw-madison-pioneers-ketamine-study-for-teens-with-ptsd 2025-01-04T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-is-a-new-year-outlier-with-its-diabetes-drug-stat-news 2025-01-04T10:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-is-a-new-year-outlier-with-its-diabetes-drug-stat-news 2025-01-04T10:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/implementation-of-a-goal-directed-care-bundle-for-intracerebral-hemorrhage-plos 2025-01-04T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implementation-of-a-goal-directed-care-bundle-for-intracerebral-hemorrhage-plos 2025-01-04T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/kaiser-permanente-pharmacist-outlines-key-challenges-in-value-based-care-implementation 2025-01-04T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaiser-permanente-pharmacist-outlines-key-challenges-in-value-based-care-implementation 2025-01-04T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-perlmutter-cancer-center-combines-ai-and-community-health-workers-to-transform-clinical-trial-access 2025-01-04T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-perlmutter-cancer-center-combines-ai-and-community-health-workers-to-transform-clinical-trial-access 2025-01-04T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/1st-stem-cell-therapy-new-hiv-drug-approved-chinadaily-com-cn 2025-01-04T06:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1st-stem-cell-therapy-new-hiv-drug-approved-chinadaily-com-cn 2025-01-04T06:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/gi-cancer-treatment-faces-immunotherapy-hurdles-expert-calls-for-better-patient-education 2025-01-04T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-cancer-treatment-faces-immunotherapy-hurdles-expert-calls-for-better-patient-education 2025-01-04T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/losartan-use-found-to-safely-ease-rdeb-symptoms-in-children-in-trial-epidermolysis-bullosa-news 2025-01-04T05:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/losartan-use-found-to-safely-ease-rdeb-symptoms-in-children-in-trial-epidermolysis-bullosa-news 2025-01-04T05:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/99mtc-tc-hynic-ipsma-shows-promise-in-prostate-cancer-imaging-urology-times 2025-01-04T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/99mtc-tc-hynic-ipsma-shows-promise-in-prostate-cancer-imaging-urology-times 2025-01-04T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/ethical-dilemma-physicians-navigate-challenges-of-repurposed-drugs-in-cancer-care 2025-01-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethical-dilemma-physicians-navigate-challenges-of-repurposed-drugs-in-cancer-care 2025-01-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incentivising-safe-sex-a-randomised-trial-of-conditional-cash-transfers-for-hiv-and-sti-prevention-in-rural-tanzania 2025-01-04T03:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incentivising-safe-sex-a-randomised-trial-of-conditional-cash-transfers-for-hiv-and-sti-prevention-in-rural-tanzania 2025-01-04T03:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-corp-submits-phase-iii-clinical-trial-of-p1101-for-pre-fibrotic-early-pmf-or 2025-01-04T02:44:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-corp-submits-phase-iii-clinical-trial-of-p1101-for-pre-fibrotic-early-pmf-or 2025-01-04T02:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/conventional-imaging-may-understage-prostate-cancer-new-data-suggest-urology-times 2025-01-04T01:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conventional-imaging-may-understage-prostate-cancer-new-data-suggest-urology-times 2025-01-04T01:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-advances-in-dna-technology-and-clinical-trials 2025-01-04T00:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-advances-in-dna-technology-and-clinical-trials 2025-01-04T00:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-pikaso-trial-a-new-hope-for-preventing-post-traumatic-osteoarthritis 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-pikaso-trial-a-new-hope-for-preventing-post-traumatic-osteoarthritis 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-new-hope-for-treatment-resistant-depression-the-rise-of-psychedelic-treatments 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-new-hope-for-treatment-resistant-depression-the-rise-of-psychedelic-treatments 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-lung-cancer-therapy-into-phase-3-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-lung-cancer-therapy-into-phase-3-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-collaborates-with-science-37-on-virtual-clinical-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-collaborates-with-science-37-on-virtual-clinical-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dengue-vaccines-and-developments-in-2025 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dengue-vaccines-and-developments-in-2025 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-biopharma-reports-positive-interim-clinical-data-for-bb-301-in-opmd-treatment-study 2025-01-03T23:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benitec-biopharma-reports-positive-interim-clinical-data-for-bb-301-in-opmd-treatment-study 2025-01-03T23:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-secures-cdsco-approval-for-novel-acid-blocker-fexuprazan-in-india 2025-01-03T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-secures-cdsco-approval-for-novel-acid-blocker-fexuprazan-in-india 2025-01-03T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/current-treatment-protocols-for-ph-all-treatment-targeted-oncology 2025-01-03T22:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/current-treatment-protocols-for-ph-all-treatment-targeted-oncology 2025-01-03T22:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-mhlw-approves-takeda-s-hyqvia-subcutaneous-injection-to-treat 2025-01-03T21:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-mhlw-approves-takeda-s-hyqvia-subcutaneous-injection-to-treat 2025-01-03T21:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/sweden-s-mendus-clears-regulatory-path-for-vididencel-registration-trial 2025-01-03T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sweden-s-mendus-clears-regulatory-path-for-vididencel-registration-trial 2025-01-03T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-data-show-potential-of-new-oral-treatments-for-gonorrhea-healio 2025-01-03T21:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-data-show-potential-of-new-oral-treatments-for-gonorrhea-healio 2025-01-03T21:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c 2025-01-03T21:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c 2025-01-03T21:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/coronary-sinus-reducer-an-overlooked-treatment-for-stable-angina 2025-01-03T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coronary-sinus-reducer-an-overlooked-treatment-for-stable-angina 2025-01-03T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-improved-responses-for-pembrolizumab-chemo-in-tnbc 2025-01-03T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-improved-responses-for-pembrolizumab-chemo-in-tnbc 2025-01-03T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/ticking-time-bomb-jimmy-carter-s-lasting-impact-on-cancer-breast-cancer-cvd-link 2025-01-03T20:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ticking-time-bomb-jimmy-carter-s-lasting-impact-on-cancer-breast-cancer-cvd-link 2025-01-03T20:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapies-that-work-10-breakthrough-technologies-2025 2025-01-03T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapies-that-work-10-breakthrough-technologies-2025 2025-01-03T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-va-fda-collaboration-will-compare-blood-thinners-in-new-head-to-head-clinical-trial 2025-01-03T18:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-va-fda-collaboration-will-compare-blood-thinners-in-new-head-to-head-clinical-trial 2025-01-03T18:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024 2025-01-03T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024 2025-01-03T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-drug-that-delays-onset-of-type-1-diabetes-weyi 2025-01-03T18:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-drug-that-delays-onset-of-type-1-diabetes-weyi 2025-01-03T18:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/qurient-receives-u-s-phase-1b-approval-for-new-immunotherapy-drug-targeting-chronic-graft 2025-01-03T17:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qurient-receives-u-s-phase-1b-approval-for-new-immunotherapy-drug-targeting-chronic-graft 2025-01-03T17:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/merck-advances-oncology-portfolio-with-new-licensing-agreements-and-clinical-trial-updates 2025-01-03T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-advances-oncology-portfolio-with-new-licensing-agreements-and-clinical-trial-updates 2025-01-03T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/elevation-oncology-promising-cancer-therapies-earn-analyst-praise 2025-01-03T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevation-oncology-promising-cancer-therapies-earn-analyst-praise 2025-01-03T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/addition-of-nab-paclitaxel-to-gemcitabine-cisplatin-in-advanced-biliary-tract-cancers 2025-01-03T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addition-of-nab-paclitaxel-to-gemcitabine-cisplatin-in-advanced-biliary-tract-cancers 2025-01-03T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/enthusiasm-for-transplant-free-strategies-for-low-risk-relapsed-hodgkin-lymphoma 2025-01-03T16:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enthusiasm-for-transplant-free-strategies-for-low-risk-relapsed-hodgkin-lymphoma 2025-01-03T16:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-can-predict-high-blood-pressure-and-related-complications-from-ecgs 2025-01-03T16:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-can-predict-high-blood-pressure-and-related-complications-from-ecgs 2025-01-03T16:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-reports-results-from-trial-of-skin-cancer-prevention-therapy 2025-01-03T15:54:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-reports-results-from-trial-of-skin-cancer-prevention-therapy 2025-01-03T15:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial-modern-retina 2025-01-03T15:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial-modern-retina 2025-01-03T15:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-eyes-near-double-digit-margins-next-year-cnbc-tv18 2025-01-03T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-eyes-near-double-digit-margins-next-year-cnbc-tv18 2025-01-03T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-drug-for-advanced-parkinson-s-disease 2025-01-03T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-drug-for-advanced-parkinson-s-disease 2025-01-03T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/speckles-within-cancerous-tumors-can-determine-best-treatments-kff-health-news 2025-01-03T14:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/speckles-within-cancerous-tumors-can-determine-best-treatments-kff-health-news 2025-01-03T14:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/treatment-approaches-for-favorable-risk-metastatic-clear-cell-rcc-expert-perspectives-on-io-and-tki-combinations 2025-01-03T14:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatment-approaches-for-favorable-risk-metastatic-clear-cell-rcc-expert-perspectives-on-io-and-tki-combinations 2025-01-03T14:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq-milestone-advancing-atopic-morningstar 2025-01-03T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq-milestone-advancing-atopic-morningstar 2025-01-03T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/news/sky-is-the-limit-for-adc-possibilities-in-nsclc-targeted-oncology 2025-01-03T14:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sky-is-the-limit-for-adc-possibilities-in-nsclc-targeted-oncology 2025-01-03T14:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/kitamaat-toddler-saved-thanks-to-clinical-trials-at-b-c-children-s-vancouver-sun 2025-01-03T14:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kitamaat-toddler-saved-thanks-to-clinical-trials-at-b-c-children-s-vancouver-sun 2025-01-03T14:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/diacarta-reports-positive-clinical-trial-data-for-its-blood-based-test-to-triage-fit-pr-newswire 2025-01-03T13:57:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diacarta-reports-positive-clinical-trial-data-for-its-blood-based-test-to-triage-fit-pr-newswire 2025-01-03T13:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-imdyllytra-approved-by-mhra-to-treat-small-cell-lung-cancer-in-adults-pmlive 2025-01-03T13:54:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-imdyllytra-approved-by-mhra-to-treat-small-cell-lung-cancer-in-adults-pmlive 2025-01-03T13:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-biotechs-challenge-pharma-giants-in-glp-1ra-market 2025-01-03T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerging-biotechs-challenge-pharma-giants-in-glp-1ra-market 2025-01-03T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-surgeon-s-spirit-and-brilliance-lift-a-whole-community-onclive 2025-01-03T13:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-surgeon-s-spirit-and-brilliance-lift-a-whole-community-onclive 2025-01-03T13:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-finds-no-significant-link-between-psoriasis-and-alzheimer-s-risk-but-notes-slight-increase-in-vascular-dementia 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-finds-no-significant-link-between-psoriasis-and-alzheimer-s-risk-but-notes-slight-increase-in-vascular-dementia 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-plus-avd-emerges-as-new-standard-for-advanced-hodgkin-lymphoma-treatment 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-plus-avd-emerges-as-new-standard-for-advanced-hodgkin-lymphoma-treatment 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-adoption-grows-in-oncology-practice-despite-validity-and-ethics-concerns-survey-reveals 2025-01-03T12:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-adoption-grows-in-oncology-practice-despite-validity-and-ethics-concerns-survey-reveals 2025-01-03T12:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/eosinophilic-esophagitis-treatment-market-2034-ema-pdma-fda-openpr-com 2025-01-03T12:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eosinophilic-esophagitis-treatment-market-2034-ema-pdma-fda-openpr-com 2025-01-03T12:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/siga-s-gains-approval-in-japan-for-orthopoxvirus-treatment-therapy 2025-01-03T12:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siga-s-gains-approval-in-japan-for-orthopoxvirus-treatment-therapy 2025-01-03T12:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-immunotherapy-in-high-risk-muscle-invasive-urothelial-cancer-urotoday 2025-01-03T12:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-immunotherapy-in-high-risk-muscle-invasive-urothelial-cancer-urotoday 2025-01-03T12:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/hepatology-month-in-review-december-2024-hcplive 2025-01-03T12:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatology-month-in-review-december-2024-hcplive 2025-01-03T12:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-oral-tyk2-inhibitor-matches-biologic-efficacy-drug-discovery-and-development 2025-01-03T11:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-oral-tyk2-inhibitor-matches-biologic-efficacy-drug-discovery-and-development 2025-01-03T11:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/research-error-sparks-unwarranted-concerns-over-heavy-metal-content-in-prenatal-vitamins 2025-01-03T11:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-error-sparks-unwarranted-concerns-over-heavy-metal-content-in-prenatal-vitamins 2025-01-03T11:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-vascular-dysfunction-in-multiple-sclerosis-patients 2025-01-03T11:15:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-vascular-dysfunction-in-multiple-sclerosis-patients 2025-01-03T11:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-autologous-neoantigen-specific-t-cell-therapy-in-metastatic-melanoma-a-phase-1-trial 2025-01-03T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-autologous-neoantigen-specific-t-cell-therapy-in-metastatic-melanoma-a-phase-1-trial 2025-01-03T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-slower-visual-processing-in-glaucoma-patients-motor-skills-remain-intact 2025-01-03T10:51:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-slower-visual-processing-in-glaucoma-patients-motor-skills-remain-intact 2025-01-03T10:51:20+00:00 hourly 0.9 https://trial.medpath.com/news/global-hiv-aids-crisis-latest-statistics-show-40-million-living-with-hiv-as-prevention-and-treatment-options-expand 2025-01-03T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-hiv-aids-crisis-latest-statistics-show-40-million-living-with-hiv-as-prevention-and-treatment-options-expand 2025-01-03T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/cathworks-completes-enrolment-in-cad-treatment-system-trial 2025-01-03T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cathworks-completes-enrolment-in-cad-treatment-system-trial 2025-01-03T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/deeper-response-predicts-better-outcomes-in-high-risk-smoldering-myeloma-nature 2025-01-03T09:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deeper-response-predicts-better-outcomes-in-high-risk-smoldering-myeloma-nature 2025-01-03T09:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-awaits-phase-iii-dragon-trial-data-can-it-fuel-further-gains 2025-01-03T09:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-awaits-phase-iii-dragon-trial-data-can-it-fuel-further-gains 2025-01-03T09:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-pharmacists-significantly-improve-ibd-treatment-outcomes-and-cost-savings 2025-01-03T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-pharmacists-significantly-improve-ibd-treatment-outcomes-and-cost-savings 2025-01-03T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic 2025-01-03T07:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic 2025-01-03T07:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-surgeon-general-pushes-for-enhanced-cancer-warning-labels-on-alcohol-products 2025-01-03T07:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-surgeon-general-pushes-for-enhanced-cancer-warning-labels-on-alcohol-products 2025-01-03T07:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-wockhardt-s-drug-miqnaf-to-treat-cabp-in-adults-the-hindu 2025-01-03T06:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-wockhardt-s-drug-miqnaf-to-treat-cabp-in-adults-the-hindu 2025-01-03T06:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-corp-to-file-ind-application-with-fda-for-phase-1b-hypertension-clinical-trial 2025-01-03T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-corp-to-file-ind-application-with-fda-for-phase-1b-hypertension-clinical-trial 2025-01-03T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-moves-to-join-lawsuit-over-glp-1-compounding-as-fda-deadline-approaches 2025-01-03T04:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-moves-to-join-lawsuit-over-glp-1-compounding-as-fda-deadline-approaches 2025-01-03T04:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/sichuan-baili-tianheng-pharmaceutical-co-ltd-voluntarily-disclosed-the-inclusion-of-bl 2025-01-03T03:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sichuan-baili-tianheng-pharmaceutical-co-ltd-voluntarily-disclosed-the-inclusion-of-bl 2025-01-03T03:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/complement-factor-h-targeting-antibody-gt103-in-refractory-non-small-cell-lung-cancer 2025-01-03T02:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complement-factor-h-targeting-antibody-gt103-in-refractory-non-small-cell-lung-cancer 2025-01-03T02:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-health-nominees-raise-concerns-over-wellness-industry-influence-on-public-health-policy 2025-01-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-health-nominees-raise-concerns-over-wellness-industry-influence-on-public-health-policy 2025-01-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intravenous-liposomal-irinotecan-in-metastatic-triple-negative-breast-cancer-after-2-prior 2025-01-03T01:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravenous-liposomal-irinotecan-in-metastatic-triple-negative-breast-cancer-after-2-prior 2025-01-03T01:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-morningstar 2025-01-03T01:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-morningstar 2025-01-03T01:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/orchestra-biomed-shares-get-shot-in-the-arm-on-solid-clinical-trial-data 2025-01-03T00:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchestra-biomed-shares-get-shot-in-the-arm-on-solid-clinical-trial-data 2025-01-03T00:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/what-s-going-on-with-acelyrin-shares-friday 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/what-s-going-on-with-acelyrin-shares-friday 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-generation-of-car-t-therapy-shows-promise-in-treating-cll 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-generation-of-car-t-therapy-shows-promise-in-treating-cll 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-swab-test-successfully-distinguishes-between-asthma-subtypes-in-breakthrough-study 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-swab-test-successfully-distinguishes-between-asthma-subtypes-in-breakthrough-study 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-doses-first-australian-patient-in-phase-1b-azer-cel-clinical-trial-proactive-investors 2025-01-02T23:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-doses-first-australian-patient-in-phase-1b-azer-cel-clinical-trial-proactive-investors 2025-01-02T23:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/bipolar-androgen-therapy-rationale-candidate-patients-and-latest-evidence-for-mcrpc-patients 2025-01-02T23:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipolar-androgen-therapy-rationale-candidate-patients-and-latest-evidence-for-mcrpc-patients 2025-01-02T23:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ib-initial-data-loncastuximab-tesirine-lpyl-plus-glofitamab-effective-safe-in-dlbcl 2025-01-02T23:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ib-initial-data-loncastuximab-tesirine-lpyl-plus-glofitamab-effective-safe-in-dlbcl 2025-01-02T23:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/boosting-reliability-ema-backs-ai-tool-for-mash-trials-citeline-news-insights 2025-01-02T22:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boosting-reliability-ema-backs-ai-tool-for-mash-trials-citeline-news-insights 2025-01-02T22:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/gi-alliance-offers-clinical-trial-opportunities-in-the-dallas-fort-worth-area-locations 2025-01-02T21:53:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-alliance-offers-clinical-trial-opportunities-in-the-dallas-fort-worth-area-locations 2025-01-02T21:53:46+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-faces-mixed-outcomes-in-clinical-trials-and-executive-changes 2025-01-02T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-faces-mixed-outcomes-in-clinical-trials-and-executive-changes 2025-01-02T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-plus-sbrt-fails-to-improve-survival-in-unresected-stage-i-ii-nsclc 2025-01-02T21:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-plus-sbrt-fails-to-improve-survival-in-unresected-stage-i-ii-nsclc 2025-01-02T21:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/very-low-dose-rituximab-for-cad-may-not-sustainably-kill-b-cells 2025-01-02T20:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/very-low-dose-rituximab-for-cad-may-not-sustainably-kill-b-cells 2025-01-02T20:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/results-from-nicotinamide-trial-highlighted-uci-mind 2025-01-02T19:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/results-from-nicotinamide-trial-highlighted-uci-mind 2025-01-02T19:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/top-10-liver-disease-stories-of-2024 2025-01-02T19:03:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-10-liver-disease-stories-of-2024 2025-01-02T19:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/college-of-medicine-researcher-receives-grant-to-further-pediatric-oncology-research 2025-01-02T18:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/college-of-medicine-researcher-receives-grant-to-further-pediatric-oncology-research 2025-01-02T18:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma 2025-01-02T18:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma 2025-01-02T18:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1 2025-01-02T18:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1 2025-01-02T18:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/top-10-fabry-disease-news-stories-of-2024 2025-01-02T17:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-10-fabry-disease-news-stories-of-2024 2025-01-02T17:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-startles-investors-with-plan-to-hook-up-with-hookipa-citeline-news-insights 2025-01-02T16:54:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-startles-investors-with-plan-to-hook-up-with-hookipa-citeline-news-insights 2025-01-02T16:54:20+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-completes-bla-submission-to-the-fda-for 2025-01-02T16:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-completes-bla-submission-to-the-fda-for 2025-01-02T16:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/for-alzheimer-agitation-a-novel-oral-nmda-inhibitor-could-be-the-next-targeted-treatment 2025-01-02T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/for-alzheimer-agitation-a-novel-oral-nmda-inhibitor-could-be-the-next-targeted-treatment 2025-01-02T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/jiangsu-recbio-technology-co-ltd-announces-completion-of-phase-iii-clinical-trial-of-the 2025-01-02T16:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jiangsu-recbio-technology-co-ltd-announces-completion-of-phase-iii-clinical-trial-of-the 2025-01-02T16:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-to-attend-the-43rd-annual-jp-morgan-healthcare-conference-stock-titan 2025-01-02T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-to-attend-the-43rd-annual-jp-morgan-healthcare-conference-stock-titan 2025-01-02T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/study-of-sacituzumab-govitecan-misses-os-end-point-in-pretreated-urothelial-carcinoma 2025-01-02T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-of-sacituzumab-govitecan-misses-os-end-point-in-pretreated-urothelial-carcinoma 2025-01-02T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/how-retail-pharmacies-are-bringing-clinical-trials-to-the-community 2025-01-02T14:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-retail-pharmacies-are-bringing-clinical-trials-to-the-community 2025-01-02T14:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-is-up-listing-in-the-usa-to-generate-liquidity-stock-titan 2025-01-02T14:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostemix-is-up-listing-in-the-usa-to-generate-liquidity-stock-titan 2025-01-02T14:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations 2025-01-02T14:39:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations 2025-01-02T14:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-biospace 2025-01-02T14:37:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-biospace 2025-01-02T14:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-files-landmark-fda-application-for-first-ever-dmd-cardiomyopathy-treatment 2025-01-02T14:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-files-landmark-fda-application-for-first-ever-dmd-cardiomyopathy-treatment 2025-01-02T14:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/benzodiazepine-agonist-treatment-for-patients-with-benzodiazepine-dependence-trials 2025-01-02T14:14:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benzodiazepine-agonist-treatment-for-patients-with-benzodiazepine-dependence-trials 2025-01-02T14:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-car-t-cell-therapy-shrinks-tumors-in-children-with-deadly-brain-cancer 2025-01-02T14:00:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-car-t-cell-therapy-shrinks-tumors-in-children-with-deadly-brain-cancer 2025-01-02T14:00:49+00:00 hourly 0.9 https://trial.medpath.com/news/silo-pharma-advances-ptsd-drug-spc-15-toward-clinical-trials-plans-2025-ind-filing 2025-01-02T13:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silo-pharma-advances-ptsd-drug-spc-15-toward-clinical-trials-plans-2025-ind-filing 2025-01-02T13:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-antidepressant-stumbles-in-first-phase-3-trial-readout-stat-news 2025-01-02T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-s-antidepressant-stumbles-in-first-phase-3-trial-readout-stat-news 2025-01-02T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-lysosomal-disorders 2025-01-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-lysosomal-disorders 2025-01-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-south-wales-to-introduce-year-long-pill-testing-trial-at-music-festivals-mixmag 2025-01-02T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-south-wales-to-introduce-year-long-pill-testing-trial-at-music-festivals-mixmag 2025-01-02T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/phone-app-may-help-treat-opioid-use-disorder-data-suggests 2025-01-02T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phone-app-may-help-treat-opioid-use-disorder-data-suggests 2025-01-02T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-completes-enrollment-in-chronic-cohort-of-its-phase-1b-2a-clinical-trial-of-nvg 2025-01-02T12:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-completes-enrollment-in-chronic-cohort-of-its-phase-1b-2a-clinical-trial-of-nvg 2025-01-02T12:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-feedback-endorses-vididencel-registration-trial-preparations-firstword-pharma 2025-01-02T12:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-ema-feedback-endorses-vididencel-registration-trial-preparations-firstword-pharma 2025-01-02T12:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/iit-guwahati-develops-precision-drug-hydrogel-for-cancer-treatment-with-fewer-side-effects 2025-01-02T12:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-guwahati-develops-precision-drug-hydrogel-for-cancer-treatment-with-fewer-side-effects 2025-01-02T12:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-s-stock-plummets-as-pfizer-axes-hemophilia-gene-therapy-pact-biospace 2025-01-02T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-s-stock-plummets-as-pfizer-axes-hemophilia-gene-therapy-pact-biospace 2025-01-02T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025 2025-01-02T12:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025 2025-01-02T12:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/high-rate-of-asymptomatic-pulmonary-involvement-found-in-early-ra-and-psa-patients 2025-01-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-rate-of-asymptomatic-pulmonary-involvement-found-in-early-ra-and-psa-patients 2025-01-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/priority-health-expands-midwest-presence-with-acquisition-of-physicians-health-plan-of-northern-indiana 2025-01-02T11:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priority-health-expands-midwest-presence-with-acquisition-of-physicians-health-plan-of-northern-indiana 2025-01-02T11:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/new-framework-proposed-to-improve-hidradenitis-suppurativa-diagnosis-and-treatment-alignment 2025-01-02T11:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-framework-proposed-to-improve-hidradenitis-suppurativa-diagnosis-and-treatment-alignment 2025-01-02T11:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-nature 2025-01-02T11:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-nature 2025-01-02T11:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-most-listened-podcast-episodes 2025-01-02T11:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-most-listened-podcast-episodes 2025-01-02T11:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/gastroenterology-month-in-review-december-2024-hcplive 2025-01-02T11:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gastroenterology-month-in-review-december-2024-hcplive 2025-01-02T11:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-insights-of-keynote-522-regimen-adoption-for-treating-triple-negative-breast-cancer 2025-01-02T10:57:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-insights-of-keynote-522-regimen-adoption-for-treating-triple-negative-breast-cancer 2025-01-02T10:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-shows-potential-for-treating-mental-health-disorders-in-people-with-cancer-and-addiction 2025-01-02T10:46:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-shows-potential-for-treating-mental-health-disorders-in-people-with-cancer-and-addiction 2025-01-02T10:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/mural-oncology-set-for-key-data-readouts-in-2025-for-nemvaleukin-alfa-in-ovarian 2025-01-02T10:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mural-oncology-set-for-key-data-readouts-in-2025-for-nemvaleukin-alfa-in-ovarian 2025-01-02T10:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/olanzapine-samidorphan-effects-on-weight-gain-an-individual-patient-data-meta-analysis 2025-01-02T10:16:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olanzapine-samidorphan-effects-on-weight-gain-an-individual-patient-data-meta-analysis 2025-01-02T10:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-trial-finding-a-cure-for-rare-childhood-cancer-opens-university-of-birmingham 2025-01-02T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-trial-finding-a-cure-for-rare-childhood-cancer-opens-university-of-birmingham 2025-01-02T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-on-track-for-key-data-readouts-and-product-launches-in-2025 2025-01-02T09:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyre-therapeutics-on-track-for-key-data-readouts-and-product-launches-in-2025 2025-01-02T09:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-and-roche-collaborate-on-promising-lung-cancer-therapy 2025-01-02T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-and-roche-collaborate-on-promising-lung-cancer-therapy 2025-01-02T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-gains-breakthrough-status-for-cancer-therapy-tipranks-com 2025-01-02T09:18:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-gains-breakthrough-status-for-cancer-therapy-tipranks-com 2025-01-02T09:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/patient-enrollment-concluded-early-in-pegasus-phase-3-pemphigus-trial-for-rilzabrutinib 2025-01-02T08:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-enrollment-concluded-early-in-pegasus-phase-3-pemphigus-trial-for-rilzabrutinib 2025-01-02T08:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-higher-mortality-and-complication-rates-for-esophagectomy-at-private-equity-owned-hospitals 2025-01-02T08:41:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-higher-mortality-and-complication-rates-for-esophagectomy-at-private-equity-owned-hospitals 2025-01-02T08:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/redefining-value-metrics-in-cancer-care-swedish-cancer-institute-director-calls-for-reform 2025-01-02T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redefining-value-metrics-in-cancer-care-swedish-cancer-institute-director-calls-for-reform 2025-01-02T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-launches-psilocybin-therapy-program-amid-regulatory-debates-and-veterans-advocacy 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-launches-psilocybin-therapy-program-amid-regulatory-debates-and-veterans-advocacy 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/travel-burden-analysis-reveals-higher-costs-for-epcoritamab-treatment-in-lymphoma-patients 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/travel-burden-analysis-reveals-higher-costs-for-epcoritamab-treatment-in-lymphoma-patients 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-faces-whistleblower-lawsuit-over-alleged-ms-drug-kickback-scheme 2025-01-02T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-faces-whistleblower-lawsuit-over-alleged-ms-drug-kickback-scheme 2025-01-02T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/pioneer-in-pediatric-leukemia-treatment-transforms-global-outcomes-through-four-decades-at-st-jude 2025-01-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneer-in-pediatric-leukemia-treatment-transforms-global-outcomes-through-four-decades-at-st-jude 2025-01-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhaoke-ophthalmology-reports-positive-trial-results-for-tab014-markets-insider 2025-01-02T03:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhaoke-ophthalmology-reports-positive-trial-results-for-tab014-markets-insider 2025-01-02T03:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-abandons-hemophilia-a-gene-therapy-program-returns-rights-to-sangamo 2025-01-02T03:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-abandons-hemophilia-a-gene-therapy-program-returns-rights-to-sangamo 2025-01-02T03:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-january-2025-rttnews 2025-01-02T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stocks-facing-fda-decision-in-january-2025-rttnews 2025-01-02T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/critical-treatment-gap-persists-for-t2-low-asthma-despite-therapeutic-advances 2025-01-02T02:54:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/critical-treatment-gap-persists-for-t2-low-asthma-despite-therapeutic-advances 2025-01-02T02:54:54+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-brings-clinical-trial-site-addition-and-change-of-pi-applications-to-online-mode 2025-01-02T02:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-brings-clinical-trial-site-addition-and-change-of-pi-applications-to-online-mode 2025-01-02T02:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/hk-inno-n-speeds-up-developing-homegrown-obesity-drug-pharma-article-kbr 2025-01-02T02:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hk-inno-n-speeds-up-developing-homegrown-obesity-drug-pharma-article-kbr 2025-01-02T02:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/china-emerges-as-global-leader-in-rare-disease-clinical-trials-since-2020 2025-01-02T02:39:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-emerges-as-global-leader-in-rare-disease-clinical-trials-since-2020 2025-01-02T02:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/korea-approves-rare-pediatric-chondrodysplasia-drug-voxzogo-policy-article-kbr 2025-01-02T02:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korea-approves-rare-pediatric-chondrodysplasia-drug-voxzogo-policy-article-kbr 2025-01-02T02:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/ai-revolutionizes-atopic-dermatitis-diagnosis-and-monitoring-with-advanced-technology-solutions 2025-01-02T02:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-revolutionizes-atopic-dermatitis-diagnosis-and-monitoring-with-advanced-technology-solutions 2025-01-02T02:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-achieves-record-breaking-58-7-early-cancer-detection-rate-despite-treatment-access-challenges 2025-01-02T01:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-england-achieves-record-breaking-58-7-early-cancer-detection-rate-despite-treatment-access-challenges 2025-01-02T01:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/will-tarlatamab-an-sclc-drug-developed-with-korea-s-help-be-introduced-here-this-year 2025-01-02T01:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/will-tarlatamab-an-sclc-drug-developed-with-korea-s-help-be-introduced-here-this-year 2025-01-02T01:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/patient-centric-strategies-reshape-oncology-trial-success-industry-experts-call-for-enhanced-engagement 2025-01-02T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-centric-strategies-reshape-oncology-trial-success-industry-experts-call-for-enhanced-engagement 2025-01-02T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tnf-inhibitors-reduce-fracture-risk-in-axial-spondyloarthritis-patients 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tnf-inhibitors-reduce-fracture-risk-in-axial-spondyloarthritis-patients 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-micurx-s-mrx-5-for-ntm-infections 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-micurx-s-mrx-5-for-ntm-infections 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/valo-health-halts-development-of-eye-disease-drug-seeks-partnership 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valo-health-halts-development-of-eye-disease-drug-seeks-partnership 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-systems-news-events 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-systems-news-events 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-rejects-neuraxpharm-and-apellis-drugs-companies-to-appeal 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-rejects-neuraxpharm-and-apellis-drugs-companies-to-appeal 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunization-most-read-stories-from-2024-drug-topics 2025-01-01T21:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunization-most-read-stories-from-2024-drug-topics 2025-01-01T21:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-starts-rhythm-pharmaceuticals-with-buy-on-obesity-potential-markets-insider 2025-01-01T18:46:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-starts-rhythm-pharmaceuticals-with-buy-on-obesity-potential-markets-insider 2025-01-01T18:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-gets-u-k-approval-for-sotatercept-for-pah-msn 2025-01-01T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-gets-u-k-approval-for-sotatercept-for-pah-msn 2025-01-01T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-quality-similar-between-youth-with-sickle-cell-disease-and-healthy-controls-but-quality-of-life-differs 2025-01-01T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-quality-similar-between-youth-with-sickle-cell-disease-and-healthy-controls-but-quality-of-life-differs 2025-01-01T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat 2025-01-01T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat 2025-01-01T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-watch-thirteen-approvals-and-eight-phase-iii-readouts 2025-01-01T15:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-watch-thirteen-approvals-and-eight-phase-iii-readouts 2025-01-01T15:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/zongertinib-continues-to-improve-outcomes-in-advanced-her2-mutant-nsclc 2025-01-01T15:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zongertinib-continues-to-improve-outcomes-in-advanced-her2-mutant-nsclc 2025-01-01T15:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/study-protocol-for-covid-19-breakthrough-infections-and-vaccine-induced-immune-plos 2025-01-01T12:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-protocol-for-covid-19-breakthrough-infections-and-vaccine-induced-immune-plos 2025-01-01T12:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/cinema-program-tackles-therapeutic-inertia-in-cardiometabolic-care-through-multi-faceted-approach 2025-01-01T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinema-program-tackles-therapeutic-inertia-in-cardiometabolic-care-through-multi-faceted-approach 2025-01-01T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-outlines-personalized-monitoring-approach-for-myeloproliferative-neoplasm-management 2025-01-01T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-outlines-personalized-monitoring-approach-for-myeloproliferative-neoplasm-management 2025-01-01T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-daiichi-sankyo-s-trop-2-adc-for-breast-cancer-bioworld 2025-01-01T10:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-daiichi-sankyo-s-trop-2-adc-for-breast-cancer-bioworld 2025-01-01T10:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/news-in-brief-sotyktu-phase-iii-win-novo-s-alhemo-approval-axsome-agitation-data-pfizer 2025-01-01T09:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/news-in-brief-sotyktu-phase-iii-win-novo-s-alhemo-approval-axsome-agitation-data-pfizer 2025-01-01T09:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/importance-of-including-paediatric-experts-in-clinical-trials 2025-01-01T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/importance-of-including-paediatric-experts-in-clinical-trials 2025-01-01T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-novel-non-opioid-multimodal-analgesic-from-xgene-pharmaceutical-reduces-pain-and-a 2025-01-01T07:43:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-novel-non-opioid-multimodal-analgesic-from-xgene-pharmaceutical-reduces-pain-and-a 2025-01-01T07:43:55+00:00 hourly 0.9 https://trial.medpath.com/news/iv-push-antibiotics-show-promise-for-faster-treatment-in-septic-shock-patients 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iv-push-antibiotics-show-promise-for-faster-treatment-in-septic-shock-patients 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-debate-car-t-cell-therapy-options-comparing-yescarta-and-breyanzi-for-lymphoma-treatment 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-debate-car-t-cell-therapy-options-comparing-yescarta-and-breyanzi-for-lymphoma-treatment 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-advances-autism-treatment-trial-cbd-based-sci-210-gets-key-israeli-approval 2025-01-01T06:54:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-advances-autism-treatment-trial-cbd-based-sci-210-gets-key-israeli-approval 2025-01-01T06:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-legal-challenge-over-tirzepatide-shortage-list-removal-agrees-to-reevaluation 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-faces-legal-challenge-over-tirzepatide-shortage-list-removal-agrees-to-reevaluation 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-s-lynn-schuchter-three-decades-of-pioneering-melanoma-treatment-and-research 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-medicine-s-lynn-schuchter-three-decades-of-pioneering-melanoma-treatment-and-research 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accc-fall-2024-innovations-in-clinical-trial-access-patient-care-and-treatment-authorization 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accc-fall-2024-innovations-in-clinical-trial-access-patient-care-and-treatment-authorization 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsies-transform-lung-cancer-diagnostics-with-5-day-result-turnaround 2025-01-01T05:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquid-biopsies-transform-lung-cancer-diagnostics-with-5-day-result-turnaround 2025-01-01T05:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-fellows-journal-seeks-input-to-shape-future-content-for-hematology-oncology-trainees 2025-01-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-fellows-journal-seeks-input-to-shape-future-content-for-hematology-oncology-trainees 2025-01-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-covid-19-causes-more-severe-kidney-function-decline-than-pneumonia 2025-01-01T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-covid-19-causes-more-severe-kidney-function-decline-than-pneumonia 2025-01-01T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-provides-2024-year-end-company-update-reinforcing-clinical 2025-01-01T02:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-provides-2024-year-end-company-update-reinforcing-clinical 2025-01-01T02:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-announces-the-initiation-of-an-investigator-initiated-trial-for-an-allogeneic-cd19 2025-01-01T02:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-announces-the-initiation-of-an-investigator-initiated-trial-for-an-allogeneic-cd19 2025-01-01T02:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-sophie-pierce-ready-to-row-the-atlantic-bbc 2025-01-01T02:24:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-sophie-pierce-ready-to-row-the-atlantic-bbc 2025-01-01T02:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/looking-ahead-to-2025-dermatology-drug-approvals 2025-01-01T02:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/looking-ahead-to-2025-dermatology-drug-approvals 2025-01-01T02:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-lung-cancer-treatment-with-bispecific-antibodies-a-review-of-amivantamab 2025-01-01T02:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-lung-cancer-treatment-with-bispecific-antibodies-a-review-of-amivantamab 2025-01-01T02:06:49+00:00 hourly 0.9